Treatment of Monoclonal Gammopathy of Undetermined Significance with Proven Osteoporosis

When MGUS is confirmed alongside proven osteoporosis, bone health becomes a specific clinical priority. This scenario warrants a targeted management approach beyond routine MGUS surveillance.

Clinical Scenario

This protocol addresses patients with monoclonal gammopathy of undetermined significance (MGUS) with proven osteoporosis — a subgroup in whom skeletal integrity requires dedicated intervention in addition to standard monitoring.

Approach

The recommended strategy for this scenario involves a specific class of bone-targeting pharmacotherapy. The complete protocol — including agent selection, monitoring parameters, and decision criteria — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/bjh.18866

The International Myeloma Working Group has suggested giving bisphosphonate therapy to MGUS patients with proven osteoporosis, but it is not yet known if this intervention reduces the incidence of fragility fractures.

View source ↗